What Does Mesoblast's(NASDAQ:MESO) Ryoncil Webinar Reveal About Evolving Graft-Versus-Host Disease Treatment?

Sonal Goyal

05 November 2026 07:54 PM AEDT

What Does Mesoblast's(NASDAQ:MESO) Ryoncil Webinar Reveal About Evolving Graft-Versus-Host Disease Treatment?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Mesoblast hosted a key opinion leader webinar titled "The Graft-versus-Host Disease Exchange" featuring Dr. Susan Prockop from Harvard Medical School and Boston Children's Hospital

• Ryoncil (remestemcel-L-rknd) was highlighted as a first-line treatment option after steroids for pediatric acute graft-versus-host disease

• Ryoncil is the first FDA-approved mesenchymal stromal cell (MSC) therapy, approved for steroid-refractory acute GvHD in pediatric patients aged 2 months and older

• The webinar included case studies and results from pivotal trials supporting evolving clinical practice in GvHD management

Mesoblast Limited(NASDAQ:MESO), a global leader in allogeneic cellular medicines for inflammatory diseases, announced on November 4, 2026 that it hosted a key opinion leader webinar focused on the evolving treatment landscape for acute graft-versus-host disease (GvHD). The webinar, titled "The Graft-versus-Host Disease Exchange - Expert Perspectives on Evolving Clinical Practice," featured Dr. Susan Prockop, Associate Professor at Harvard Medical School and Attending Physician and Director at Boston Children's Hospital.

Expert Perspectives on Ryoncil in Clinical Practice

Dr. Prockop provided an overview of Ryoncil (remestemcel-L-rknd) as a treatment paradigm in the management of acute graft-versus-host disease. The presentation covered its use as a first-line therapy after steroids, highlighting case studies and discussing results from pivotal clinical trials. Ryoncil is the first FDA-approved mesenchymal stromal cell therapy, authorized for the treatment of steroid-refractory acute GvHD in pediatric patients aged 2 months and older. The webinar explored how the availability of this cellular medicine is influencing clinical decision-making among pediatric transplant specialists, particularly as it relates to the timing of intervention following initial steroid treatment. A replay of the webcast was made available for healthcare professionals and investors who were unable to attend the live session.

Mesoblast's Broader Development Pipeline

Beyond its approved indication in pediatric steroid-refractory acute GvHD, Mesoblast is developing Ryoncil for additional inflammatory conditions, including steroid-refractory acute GvHD in adult patients and biologic-resistant inflammatory bowel disease. The company's second therapeutic platform, rexlemestrocel-L, is being developed for heart failure and chronic low back pain. Mesoblast has established commercial partnerships in Japan, Europe, and China to support the global distribution of its cellular medicines. The company holds an extensive intellectual property portfolio with over 1,000 granted patents or Patent applications covering mesenchymal stromal cell compositions, Manufacturing methods, and indications, with commercial protection extending through at least 2044 across all major markets.

About Mesoblast and Its Technology Platform

Mesoblast is focused on developing allogeneic, or off-the-shelf, cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's proprietary mesenchymal lineage cell therapy technology platform operates by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, targeting the underlying inflammatory process. The company's proprietary manufacturing processes Yield industrial-scale, cryopreserved, off-the-shelf cellular medicines with defined pharmaceutical release criteria, designed to be readily available to patients globally. Mesoblast maintains operations in Australia, the United States, and Singapore, and is listed on both the Australian Securities Exchange under the ticker MSB and on Nasdaq under the ticker MESO.

The Broader Picture

The webinar underscores the growing clinical interest in Ryoncil's role in the GvHD treatment algorithm. As the first and only FDA-approved mesenchymal stromal cell therapy, Ryoncil occupies a unique position in pediatric transplant medicine. The company's ongoing development of both remestemcel-L and rexlemestrocel-L across multiple inflammatory disease indications suggests a broadening approach to its allogeneic cellular medicine platform. For the full prescribing information, Mesoblast directs healthcare professionals to www.ryoncil.com.

FAQs

Q: What is Ryoncil used for?

A: Ryoncil (remestemcel-L-rknd) is FDA-approved for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. It is the first approved mesenchymal stromal cell therapy.

Q: Who presented at the Mesoblast webinar?

A: Dr. Susan Prockop, Associate Professor at Harvard Medical School and Attending Physician and Director at Boston Children's Hospital, presented as the key opinion leader at the webinar.

Q: What other indications is Mesoblast developing Ryoncil for?

A: Mesoblast is developing Ryoncil for additional indications including steroid-refractory acute GvHD in adults and biologic-resistant inflammatory bowel disease.

Q: Where is Mesoblast listed?

A: Mesoblast is dual-listed on the Australian Securities Exchange (ASX:MSB) and on Nasdaq (NASDAQ:MESO).

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.